---
document_datetime: 2025-12-02 04:56:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ellaone.html
document_name: ellaone.html
version: success
processing_time: 0.1328833
conversion_datetime: 2025-12-24 23:58:39.735342
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# ellaOne

[RSS](/en/individual-human-medicine.xml/66614)

##### Authorised

This medicine is authorised for use in the European Union

ulipristal acetate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on ellaOne](#news-on)
- [More information on ellaOne](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for ellaOne. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ellaOne.

Expand section

Collapse section

## What is ellaOne?

EllaOne is a medicine that contains the active substance ulipristal acetate. It is available as tablets (30 mg).

## What is ellaOne used for?

EllaOne is a female emergency contraceptive to be taken within 120 hours (five days) of unprotected sex or contraceptive failure (such as a tear in a condom during sex).

The medicine can be obtained without a prescription.

## How is ellaOne used?

EllaOne is taken as one tablet by mouth as soon as possible, but no later than 120 hours, after unprotected sex or contraceptive failure. If the woman vomits within three hours of taking the medicine she should take another tablet. EllaOne can be taken at any time during the menstrual cycle.

If a woman's menstrual period is late or in case of symptoms of pregnancy, pregnancy should be excluded before ellaOne is taken.

## How does ellaOne work?

For pregnancy to occur there has to be ovulation (release of eggs) followed by the fertilisation of the egg (fusion with a sperm) and implantation in the womb. The sex hormone progesterone plays a role in the timing of ovulation and in preparing the lining of womb to receive the fertilised egg.

The active substance in ellaOne, ulipristal acetate, acts as a progesterone receptor modulator. This means that it attaches to the receptors that progesterone normally attaches to, preventing the hormone from having its effect. Through its actions on the progesterone receptors, ellaOne prevents pregnancies mainly by preventing or delaying ovulation. If ovulation has already occurred, ellaOne is no longer effective.

## How has ellaOne been studied?

In one main study, ellaOne was given to 1,533 women (aged on average 24 years) who had requested emergency contraception between two and five days after unprotected sex or contraceptive failure. The main measure of effectiveness was the number of women who did not become pregnant. This number was then compared with the number of women who would have been expected to become pregnant if they had not taken a contraceptive. This number was calculated from published pregnancy rates.

An additional study compared ellaOne with levonorgestrel (another medicine used in emergency contraception). This study included women who took the medicine within two days of unprotected sex or contraceptive failure.

## What benefit has ellaOne shown during the studies?

EllaOne was effective as an emergency contraceptive, reducing the number of unintended pregnancies. Of the women who completed the main study, 2.1% (26 out of 1,241) became pregnant. This is less than the 5.5% of women who would have been expected to become pregnant if they had not taken any contraceptive. EllaOne therefore prevented about three-fifths of the pregnancies.

The additional study, which included women who took the medicine within two days of unprotected sex or contraceptive failure, supported the effectiveness of ellaOne. In this study, ellaOne was as effective as levonorgestrel at preventing pregnancies.

## What is the risk associated with ellaOne?

The most common side effects with ellaOne are headache, nausea (feeling sick), abdominal pain (stomach ache) and dysmenorrhea (period pains). For the full list of all side effects and restrictions, see the package leaflet.

## Why has ellaOne been approved?

The CHMP decided that ellaOne's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of ellaOne?

A risk management plan has been developed to ensure that ellaOne is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for ellaOne, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about ellaOne

The European Commission granted a marketing authorisation valid throughout the European Union for ellaOne on 15 May 2009.

For more information about treatment with ellaOne, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

ellaOne : EPAR - Summary for the public

English (EN) (80.06 KB - PDF)

**First published:** 03/06/2009

**Last updated:** 06/02/2015

[View](/en/documents/overview/ellaone-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-315)

български (BG) (107.11 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/bg/documents/overview/ellaone-epar-summary-public_bg.pdf)

español (ES) (103.64 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/es/documents/overview/ellaone-epar-summary-public_es.pdf)

čeština (CS) (104.49 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/cs/documents/overview/ellaone-epar-summary-public_cs.pdf)

dansk (DA) (80.36 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/da/documents/overview/ellaone-epar-summary-public_da.pdf)

Deutsch (DE) (105.12 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/de/documents/overview/ellaone-epar-summary-public_de.pdf)

eesti keel (ET) (80.3 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/et/documents/overview/ellaone-epar-summary-public_et.pdf)

ελληνικά (EL) (129.29 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/el/documents/overview/ellaone-epar-summary-public_el.pdf)

français (FR) (103.73 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/fr/documents/overview/ellaone-epar-summary-public_fr.pdf)

hrvatski (HR) (100.41 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/hr/documents/overview/ellaone-epar-summary-public_hr.pdf)

italiano (IT) (102.98 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/it/documents/overview/ellaone-epar-summary-public_it.pdf)

latviešu valoda (LV) (103.65 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/lv/documents/overview/ellaone-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (198.69 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/lt/documents/overview/ellaone-epar-summary-public_lt.pdf)

magyar (HU) (125.1 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/hu/documents/overview/ellaone-epar-summary-public_hu.pdf)

Malti (MT) (106.77 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/mt/documents/overview/ellaone-epar-summary-public_mt.pdf)

Nederlands (NL) (103.76 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/nl/documents/overview/ellaone-epar-summary-public_nl.pdf)

polski (PL) (129.22 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/pl/documents/overview/ellaone-epar-summary-public_pl.pdf)

português (PT) (103.42 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/pt/documents/overview/ellaone-epar-summary-public_pt.pdf)

română (RO) (124.73 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/ro/documents/overview/ellaone-epar-summary-public_ro.pdf)

slovenčina (SK) (126.87 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/sk/documents/overview/ellaone-epar-summary-public_sk.pdf)

slovenščina (SL) (123.91 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/sl/documents/overview/ellaone-epar-summary-public_sl.pdf)

Suomi (FI) (102.76 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/fi/documents/overview/ellaone-epar-summary-public_fi.pdf)

svenska (SV) (103.37 KB - PDF)

**First published:**

03/06/2009

**Last updated:**

06/02/2015

[View](/sv/documents/overview/ellaone-epar-summary-public_sv.pdf)

ellaOne :  EPAR - Risk management plan

English (EN) (1.29 MB - PDF)

**First published:** 09/01/2025

[View](/en/documents/rmp/ellaone-epar-risk-management-plan_en.pdf)

## Product information

ellaOne: EPAR - Product information

English (EN) (525.06 KB - PDF)

**First published:** 13/11/2009

**Last updated:** 29/09/2025

[View](/en/documents/product-information/ellaone-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-831)

български (BG) (640.64 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/bg/documents/product-information/ellaone-epar-product-information_bg.pdf)

español (ES) (511.17 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/es/documents/product-information/ellaone-epar-product-information_es.pdf)

čeština (CS) (689.49 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/cs/documents/product-information/ellaone-epar-product-information_cs.pdf)

dansk (DA) (520.75 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/da/documents/product-information/ellaone-epar-product-information_da.pdf)

Deutsch (DE) (555.46 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/de/documents/product-information/ellaone-epar-product-information_de.pdf)

eesti keel (ET) (534.5 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/et/documents/product-information/ellaone-epar-product-information_et.pdf)

ελληνικά (EL) (648.73 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/el/documents/product-information/ellaone-epar-product-information_el.pdf)

français (FR) (536.75 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/fr/documents/product-information/ellaone-epar-product-information_fr.pdf)

hrvatski (HR) (609.26 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/hr/documents/product-information/ellaone-epar-product-information_hr.pdf)

íslenska (IS) (532.74 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/is/documents/product-information/ellaone-epar-product-information_is.pdf)

italiano (IT) (525.82 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/it/documents/product-information/ellaone-epar-product-information_it.pdf)

latviešu valoda (LV) (599.41 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/lv/documents/product-information/ellaone-epar-product-information_lv.pdf)

lietuvių kalba (LT) (560.93 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/lt/documents/product-information/ellaone-epar-product-information_lt.pdf)

magyar (HU) (672.79 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/hu/documents/product-information/ellaone-epar-product-information_hu.pdf)

Malti (MT) (640.09 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/mt/documents/product-information/ellaone-epar-product-information_mt.pdf)

Nederlands (NL) (570.52 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/nl/documents/product-information/ellaone-epar-product-information_nl.pdf)

norsk (NO) (525.7 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/no/documents/product-information/ellaone-epar-product-information_no.pdf)

polski (PL) (596.74 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/pl/documents/product-information/ellaone-epar-product-information_pl.pdf)

português (PT) (519.79 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/pt/documents/product-information/ellaone-epar-product-information_pt.pdf)

română (RO) (591.11 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/ro/documents/product-information/ellaone-epar-product-information_ro.pdf)

slovenčina (SK) (639.98 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/sk/documents/product-information/ellaone-epar-product-information_sk.pdf)

slovenščina (SL) (618.26 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/sl/documents/product-information/ellaone-epar-product-information_sl.pdf)

Suomi (FI) (553.92 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/fi/documents/product-information/ellaone-epar-product-information_fi.pdf)

svenska (SV) (507.39 KB - PDF)

**First published:**

13/11/2009

**Last updated:**

29/09/2025

[View](/sv/documents/product-information/ellaone-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000301541 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

ellaOne: EPAR - All Authorised presentations

English (EN) (14.11 KB - PDF)

**First published:** 17/07/2009

**Last updated:** 21/11/2017

[View](/en/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-479)

български (BG) (45.52 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/bg/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.08 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/es/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.77 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/cs/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.79 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/da/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.35 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/de/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.7 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/et/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.66 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/el/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_el.pdf)

français (FR) (15.83 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/fr/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (20.98 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/hr/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.77 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/is/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.58 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/it/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.75 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/lv/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.6 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/lt/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.26 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/hu/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (29.62 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/mt/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.8 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/nl/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.76 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/no/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_no.pdf)

polski (PL) (21.49 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/pl/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.12 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/pt/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.32 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/ro/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.98 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/sk/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.27 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/sl/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.1 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/fi/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.75 KB - PDF)

**First published:**

17/07/2009

**Last updated:**

21/11/2017

[View](/sv/documents/all-authorised-presentations/ellaone-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine ellaOne Active substance ulipristal International non-proprietary name (INN) or common name ulipristal acetate Therapeutic area (MeSH) Contraception, Postcoital Anatomical therapeutic chemical (ATC) code G03AD02

### Pharmacotherapeutic group

- Sex hormones and modulators of the genital system
- Emergency contraceptives

### Therapeutic indication

Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

## Authorisation details

EMA product number EMEA/H/C/001027 Marketing authorisation holder

Laboratoire HRA Pharma

200 avenue de Paris

Marketing authorisation issued 15/05/2009 Revision 36

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

ellaOne : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (187.66 KB - PDF)

**First published:** 03/04/2025

**Last updated:** 29/09/2025

[View](/en/documents/procedural-steps-after/ellaone-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

ellaOne : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (184.29 KB - PDF)

**First published:** 13/11/2009

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/ellaone-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

ellaOne-H-C-PSUSA-00003074-202105 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/28536/2022

English (EN) (129.03 KB - PDF)

**First published:** 21/03/2022

[View](/en/documents/scientific-conclusion/ellaone-h-c-psusa-00003074-202105-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

ellaOne-H-C-1027-II-0021 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/73099/2015

English (EN) (2.33 MB - PDF)

**First published:** 06/02/2015

**Last updated:** 06/02/2015

[View](/en/documents/variation-report/ellaone-h-c-1027-ii-0021-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for ellaOne

Adopted

Reference Number: EMA/CHMP/717569/2014

English (EN) (67.16 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ellaone_en.pdf)

ellaOne-H-C-1027-A31-0028 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/464144/2014

English (EN) (471.4 KB - PDF)

**First published:** 24/10/2014

**Last updated:** 24/10/2014

[View](/en/documents/variation-report/ellaone-h-c-1027-a31-0028-epar-assessment-report-article-31_en.pdf)

ellaOne-H-C-1027-A31-0028 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (58.23 KB - PDF)

**First published:** 24/10/2014

**Last updated:** 24/10/2014

[View](/en/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

[Other languages (22)](#file-language-dropdown-767)

български (BG) (88.09 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/bg/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_bg.pdf)

español (ES) (54.32 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/es/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_es.pdf)

čeština (CS) (82.91 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/cs/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_cs.pdf)

dansk (DA) (54.95 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/da/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_da.pdf)

Deutsch (DE) (58.99 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/de/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_de.pdf)

eesti keel (ET) (59.75 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/et/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_et.pdf)

ελληνικά (EL) (86.08 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/el/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_el.pdf)

français (FR) (57.78 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/fr/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_fr.pdf)

hrvatski (HR) (132.63 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/hr/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_hr.pdf)

italiano (IT) (56 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/it/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_it.pdf)

latviešu valoda (LV) (80.65 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/lv/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_lv.pdf)

lietuvių kalba (LT) (82.02 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/lt/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_lt.pdf)

magyar (HU) (79.42 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/hu/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_hu.pdf)

Malti (MT) (83.05 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/mt/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_mt.pdf)

Nederlands (NL) (53.13 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/nl/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_nl.pdf)

polski (PL) (81.72 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/pl/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_pl.pdf)

português (PT) (56.52 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/pt/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_pt.pdf)

română (RO) (79.58 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/ro/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_ro.pdf)

slovenčina (SK) (74.18 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/sk/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_sk.pdf)

slovenščina (SL) (77.34 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/sl/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_sl.pdf)

Suomi (FI) (56.86 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/fi/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_fi.pdf)

svenska (SV) (57.09 KB - PDF)

**First published:**

24/10/2014

**Last updated:**

24/10/2014

[View](/sv/documents/scientific-conclusion/ellaone-h-c-1027-a31-0028-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_sv.pdf)

## Initial marketing authorisation documents

ellaOne: EPAR - Public assessment report

English (EN) (776.46 KB - PDF)

**First published:** 03/06/2009

**Last updated:** 03/06/2009

[View](/en/documents/assessment-report/ellaone-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion for Ellaone

Reference Number: EMEA/CHMP/167750/2009

English (EN) (30.29 KB - PDF)

**First published:** 20/03/2009

**Last updated:** 20/03/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-ellaone_en.pdf)

#### News on ellaOne

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

[EMA recommends availability of ellaOne emergency contraceptive without prescription](/en/news/ema-recommends-availability-ellaone-emergency-contraceptive-without-prescription) 21/11/2014

[Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight](/en/news/levonorgestrel-ulipristal-remain-suitable-emergency-contraceptives-all-women-regardless-bodyweight) 24/07/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

[Review of emergency contraceptives started](/en/news/review-emergency-contraceptives-started) 24/01/2014

- [Emergency contraceptives](/en/medicines/human/referrals/emergency-contraceptives)

#### More information on ellaOne

- [EMEA-000305-PIP01-08-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000305-pip01-08-m02)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/09/2025

## Share this page

[Back to top](#main-content)